Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation

Table 1 Baseline characteristics of patients with diabetes mellitus and without diabetes mellitus n (%)

Category	Diabetic (n = 295)	Non-diabetic (n = 1336)	Value	df	P value
Sex			2.999	1	0.083
Male	278 (94.2)	1218 (91.2)
Female	17 (5.8)	118 (8.8)
Age, yr			23.690	1	0.000
≤ 50	96 (32.5)	643 (48.1)
> 50	199 (67.5)	693 (51.9)
Tumor size			4.333	3	0.228
≤ 3	163 (55.3)	704 (52.7)
3-5	85 (28.8)	350 (26.2)
5-7	28 (9.5)	157 (11.8)
> 7	19 (6.4)	125 (9.4)
Number of tumor nodules			0.245	2	0.885
Singer	147 (49.8)	666 (49.9)
≥ 2, ≤ 3	72 (24.4)	341 (25.5)
≥ 4	76 (25.8)	329 (24.6)
Venous invasion			0.641	1	0.423
Absent	256 (86.8)	1135 (85.0)
Present	39 (13.2)	201 (15.0)
Lymph node invasion			1.272	1	0.304
Absent	284 (96.3)	1265 (94.7)
Present	11 (3.7)	71 (5.3)
Capsular invasion			0.005	1	0.942
Absent	259 (87.8)	1175 (87.9)
Present	36 (12.2)	161 (12.1)
Microsatellite lesions			0.430	1	0.512
Absent	234 (79.3)	1082 (81.0)
Present	61 (20.7)	254 (19.0)
Edmondson			4.359	2	0.108
1	12 (4.1)	27 (2.0)
2	168 (56.9)	797 (59.7)
3 + 4 + 5	115 (39.0)	512 (38.3)
Serum AFP level, in ng/mL			5.518	4	0.236
< 200	231 (78.3)	966 (72.3)
200-400	18 (6.1)	87 (6.5)
400-1000	17 (5.8)	122 (9.1)
1000-2000	13 (4.4)	65 (4.9)
> 2000	16 (5.4)	96 (7.2)
MELD score			14.184	2	0.001
< 10	97 (32.9)	582 (43.6)
10-15	94 (31.9)	406 (30.4)
> 15	104 (35.3)	348 (26.0)
Child-Pugh score			12.456	2	0.002
A	125 (42.4)	715 (53.5)
B	104 (35.3)	396 (29.6)
C	66 (22.4)	225 (16.8)
Fasting blood glucose, in mmol/L			678.412	1	0.000
< 7	101 (34.2)	1273 (95.3)
≥ 7	194 (65.8)	63 (4.7)
BMI, in kg/m2			7.937	3	0.047
< 18.5	19 (6.4)	69 (5.2)
18.5-24	164 (55.6)	856 (64.1)
24-28	84 (28.5)	295 (22.1)
> 28	28 (9.5)	116 (8.7)
ALP, in IU/L			1.546	1	0.214
≤ 112	179 (60.7)	862 (64.5)
> 112	116 (39.3)	474 (35.5)
GGT, in IU/L			2.196	1	0.138
≤ 54	107 (36.3)	547 (40.9)
> 54	188 (63.7)	789 (59.1)
AST, in IU/L			2.682	2	0.262
≤ 40	102 (34.6)	481 (36.0)
40-80	107 (36.3)	526 (39.4)
> 80	86 (29.2)	329 (24.6)
ALT, in IU/L			3.142	2	0.208
≤ 40	121 (41.0)	566 (42.4)
40-80	105 (35.6)	517 (38.7)
> 80	69 (23.4)	253 (18.9)
TC, in mmol/L			22.536	1	0.000
≤ 1.7	250 (84.7)	1245 (93.2)
> 1.7	45 (15.3)	91 (6.8)
CH, in mmol/L			3.840	2	0.147
< 3.88	185 (62.7)	865 (64.7)
3.88-5.2	67 (22.7)	329 (24.6)
> 5.2	43 (14.6)	142 (10.6)
Pre-LT antitumor therapy			0.451	2	0.798
No	219 (74.5)	1016 (76.2)
local therapy	48 (16.3)	209 (15.7)
Resection	27 (9.2)	109 (8.2)
HBeAg			0.670	1	0.413
Negative	232 (78.6)	1021 (76.4)
Positive	63 (21.4)	315 (23.6)
HBV DNA, in IU/mL			6.140	1	0.013
Negative, ≤ 103	191 (64.7)	760 (56.9)
Positive, ≥ 103	104 (35.3)	576 (43.1)
Post-LT HBV recurrence			0.217	1	0.740
No	285 (96.6)	1283 (96.0)
Yes	10 (3.4)	53 (4.0)

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.